RESMED INC (RMD)
$240.33+$4.57 (+1.94%) Today
Brett Sandercock - OfficerResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea, combined with aging populations and increasing prevalence of obesity, is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 4 | 22,973 | $4.89M |
| Option exercise | 6 | 29,946 | |
| Tax withholding / forfeiture | 1 | 268.74 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
101 Form 4 filings on record, the earliest from Oct 2, 2024, newest first. Filing history page 1 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Michael J. Farrell - Officer | Option exercise | ResMed Common Stock | 4,991 | $146.34 | $730K | |
| Michael J. Farrell - Officer | Open-market sale | ResMed Common Stock | 4,991 | $205.69 | $1.03M | |
| Michael J. Farrell - Officer | Option exercise | ResMed Common Stock Options | 4,991 | $0.00 | - | |
| Peter C. Farrell - Director | Open-market sale | ResMed Common Stock | 8,000 | $225.00 | $1.80M | |
| Michael J. Farrell - Officer | Option exercise | ResMed Common Stock | 4,991 | $146.34 | $730K | |
| Michael J. Farrell - Officer | Open-market sale | ResMed Common Stock | 4,991 | $218.55 | $1.09M | |
| Michael J. Farrell - Officer | Option exercise | ResMed Common Stock Options | 4,991 | $0.00 | - | |
| Michael J. Farrell - Officer | Option exercise | ResMed Common Stock Options | 4,991 | $0.00 | - | |
| Michael J. Farrell - Officer | Option exercise | ResMed Common Stock | 4,991 | $146.34 | $730K | |
| Michael J. Farrell - Officer | Open-market sale | ResMed Common Stock | 4,991 | $193.96 | $968K | |
 Michael J. Rider - Officer | Tax withholding / forfeiture | ResMed Common Stock | 268.74 | $190.57 | $51K | |
| Michael J. Farrell - Officer | Option exercise | ResMed Common Stock | 4,991 | $146.34 | $730K | |
| Michael J. Farrell - Officer | Open-market sale | ResMed Common Stock | 4,991 | $207.82 | $1.04M | |
| Michael J. Farrell - Officer | Option exercise | ResMed Common Stock Options | 4,991 | $0.00 | - | |
| Michael J. Farrell - Officer | Option exercise | ResMed Common Stock | 4,991 | $146.34 | $730K | |
| Michael J. Farrell - Officer | Open-market sale | ResMed Common Stock | 4,991 | $225.50 | $1.13M | |
| Michael J. Farrell - Officer | Option exercise | ResMed Common Stock Options | 4,991 | $0.00 | - | |
| Brett Sandercock - Officer | Open-market sale | ResMed Common Stock | 1,000 | $224.31 | $224K | |
| Peter C. Farrell - Director | Open-market sale | ResMed Common Stock | 2,000 | $225.00 | $450K | |
| Michael J. Farrell - Officer | Open-market sale | ResMed Common Stock | 4,991 | $251.03 | $1.25M | |
| Michael J. Farrell - Officer | Option exercise | ResMed Common Stock Options | 4,991 | $0.00 | - | |
| Michael J. Farrell - Officer | Option exercise | ResMed Common Stock | 4,991 | $146.34 | $730K | |
| Peter C. Farrell - Director | Open-market sale | ResMed Common Stock | 2,000 | $260.22 | $520K | |
| Brett Sandercock - Officer | Open-market sale | ResMed Common Stock | 1,000 | $254.30 | $254K | |
| Michael J. Farrell - Officer | Option exercise | ResMed Common Stock | 4,991 | $146.34 | $730K | |
| Michael J. Farrell - Officer | Open-market sale | ResMed Common Stock | 4,991 | $273.78 | $1.37M | |
| Michael J. Farrell - Officer | Option exercise | ResMed Common Stock Options | 4,991 | $0.00 | - | |
| Peter C. Farrell - Director | Open-market sale | ResMed Common Stock | 2,000 | $251.31 | $503K | |
| Michael J. Rider - Officer | Open-market sale | ResMed Common Stock | 50 | $260.00 | $13K | |
| Brett Sandercock - Officer | Open-market sale | ResMed Common Stock | 1,000 | $257.03 | $257K | |
| Peter C. Farrell - Director | Open-market sale | ResMed Common Stock | 2,000 | $248.83 | $498K | |
| Michael J. Farrell - Officer | Option exercise | ResMed Common Stock | 4,991 | $146.34 | $730K | |
| Michael J. Farrell - Officer | Open-market sale | ResMed Common Stock | 4,991 | $248.46 | $1.24M | |
| Michael J. Farrell - Officer | Option exercise | ResMed Common Stock Options | 4,991 | $0.00 | - | |
| Brett Sandercock - Officer | Open-market sale | ResMed Common Stock | 1,000 | $241.75 | $242K | |
| Michael J. Rider - Officer | Open-market sale | ResMed Common Stock | 50 | $241.75 | $12K | |
| Brett Sandercock - Officer | Open-market sale | ResMed Common Stock | 1,000 | $244.16 | $244K | |
| Michael J. Rider - Officer | Open-market sale | ResMed Common Stock | 50 | $244.16 | $12K | |
| Nicole Mowad-Nassar - Director | Grant or award | ResMed Common Stock Options | 1,331 | $250.52 | $333K | |
| Peter C. Farrell - Director | Grant or award | ResMed Common Stock Options | 1,331 | $250.52 | $333K | |
| Michael J. Farrell - Officer | Grant or award | ResMed Common Stock Options | 33,288 | $250.52 | $8.34M | |
| Witte Jan de - Director | Open-market sale | ReMed Common Stock | 2,055 | $255.00 | $524K | |
| Witte Jan de - Director | Grant or award | ReMed Common Stock | 1,073 | $0.00 | - | |
| Peter C. Farrell - Director | Grant or award | ResMed Common Stock | 536 | $0.00 | - | |
 Christopher Delorefice - Director | Grant or award | ResMed Common Stock | 1,073 | $0.00 | - |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Farrell Michael J. | Officer, Director | 4,991 | $1.03M | View on EDGAR | |
| Peter C Farrell | Director | 8,000 | $1.80M | View on EDGAR | |
| - | - | - | - | View on EDGAR |
RESMED INC (RMD) had 5 insider filings in the last 90 days, with the most recent on 2026-08-11. The full record for RMD runs to 101 Form 4 filings, the earliest from 2024-10-02. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of RMD were filed in the last 90 days.
4 insider sales of RMD were filed in the last 90 days, totaling $4.89M.
This page tracks RMD Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add RMD to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
